CSL Ltd. Newsletter
-
Global Pulmonary Drugs Market is Expected to Showcase a Significant Growth by 2030, Predicts DelveInsight | Key Companies - F. Hoffmann-La Roche, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Sanofi, Grifols, Regeneron
25 Apr 2024 17:00 GMT
… others
Pulmonary Drugs Market Assessment
Pulmonary Drugs Market Segmentation
Pulmonary Drugs Market Segmentation … . Co., Ltd., Pulmotect, Inc., Tetherex Pharmaceutical, CSL Behring, AstraZeneca, Novartis, Genentech, Vertex …
-
8 of the most expensive drugs in biopharma: Unraveling the costliest medications
25 Apr 2024 12:20 GMT
… first U.S. Food and Drug Administration (FDA)-approved gene … uniQure, CSL Behring
On our list of the most expensive drugs, Hemgenix … over a lifetime. CSL Behring told Fierce Pharma at the time of … 5 million price tag, the drug would generate “significant cost …
-
This fundie says CSL is a $500 stock
25 Apr 2024 03:17 GMT
… positive on the outlook for CSL. After a period of high … donor fees and underutilised assets, CSL is now seeing volume growth … surrounding the new weight-loss drugs known as GLP-1s. This …
-
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
24 Apr 2024 11:05 GMT
… Renal Pharma (with Fresenius Medical Care). The parent company, CSL (ASX: CSL; USOTC … disease, taking concomitant potassium-increasing drugs (e.g., potassium supplements, … ), dizziness, hyperkalemia, and anemia. Drug interactions
Renin-Angiotensin System (RAS …
-
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
24 Apr 2024 09:44 GMT
… Renal Pharma (with Fresenius Medical Care).
The parent company, CSL (ASX: CSL; USOTC … and has been granted Orphan Drug Designation for the treatment of … by the US Food and Drug Administration in February 2023 based …
-
FDA approves Pfizer’s hemophilia B gene therapy
26 Apr 2024 11:35 GMT
… to severe hemophilia B. The pharma company will market the gene … approved for hemophilia B, after CSL received a regulatory nod for …
-
Deep quantum modeling enables new drugs for hereditary angioedema
23 Apr 2024 16:19 GMT
… subcutaneous (human), or Haegarda (CSL Behring), also has been … other diseases.
“All our drugs feature novel molecular structures,” … any similarities with current drugs, Prakash said, with … chemical structures and “find drug candidates that are inaccessible …
-
CSL Vifor Offers Marketing Campaign to Reverse Alleged Anti-Competitive Pract...
22 Apr 2024 13:49 GMT
… Vifor Pharma';s office in Switzerland/iStock, Denis Linine
CSL Vifor … , formerly known as Vifor Pharma, has proposed … Pharmacosmos’ iron deficiency drug Monofer (ferric derisomaltose), which is the main competition for CSL …
-
CSL Vifor offers campaign to mollify EC in antitrust probe
22 Apr 2024 09:45 GMT
… messaging issued by Vifor Pharma about Pharmacosmos’ Monofer, a rival … that Vifor Pharma – which was acquired by CSL in an … and allow competitors, including Pharmacosmos, to reference the information … the alleged misconduct.
Pharmacosmos told Reuters that it …
-
Increasing mRNA Product Stability with Lyophilization
24 Apr 2024 21:59 GMT
… therapeutics. While encapsulation of mRNA drug substances in lipid nanoparticles ( … Therapeutics, in collaboration with CSL, that received the first … contributing editor to Pharmaceutical Technology®.
Article details
Pharmaceutical Technology
Innovations in …